{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:21:11Z","timestamp":1787761271538,"version":"build-2784847793"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Ibrutinib, a Bruton's tyrosine kinase inhibitor (TKI) used primarily in the treatment of hematologic malignancies, has been associated with increased incidence of atrial fibrillation (AF), with limited data on its association with other tachyarrhythmias. There are limited reports that comprehensively analyze atrial and ventricular arrhythmia (VA) burden in patients on ibrutinib. We hypothesized that long-term event monitors could reveal a high burden of atrial and VAs in patients on ibrutinib.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A retrospective data analysis at a single center using electronic medical records database search tools and individual chart review was conducted to identify consecutive patients who had event monitors while on ibrutinib therapy.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Seventy-two patients were included in the analysis with a mean age of 76.9 \u00b1 9.9 years and 13 patients (18%) had a diagnosis of AF prior to the ibrutinib therapy. During ibrutinib therapy, most common arrhythmias documented were non-AF supraventricular tachycardia (<jats:italic>n<\/jats:italic> = 32, 44.4%), AF (<jats:italic>n<\/jats:italic> = 32, 44%), and non-sustained ventricular tachycardia (<jats:italic>n<\/jats:italic> = 31, 43%). Thirteen (18%) patients had &amp;gt;1% premature atrial contraction burden; 16 (22.2%) patients had &amp;gt;1% premature ventricular contraction burden. In 25% of the patients, ibrutinib was held because of arrhythmias. Overall 8.3% of patients were started on antiarrhythmic drugs during ibrutinib therapy to manage these arrhythmias.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> In this large dataset of ambulatory cardiac monitors on patients treated with ibrutinib, we report a high prevalence of atrial and VAs, with a high incidence of treatment interruption secondary to arrhythmias and related symptoms. Further research is warranted to optimize strategies to diagnose, monitor, and manage ibrutinib-related arrhythmias.<\/jats:p>","DOI":"10.3389\/fcvm.2021.792310","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T06:25:52Z","timestamp":1641191152000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Arrhythmia Patterns in Patients on Ibrutinib"],"prefix":"10.3389","volume":"8","author":[{"given":"Muhammad","family":"Fazal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridhima","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv M.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Perino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Baykaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June-Wha","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e001049","DOI":"10.1136\/openhrt-2019-001049","article-title":"High incidence of atrial fibrillation in patients treated with ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open Heart."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica."},{"key":"B3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation."},{"key":"B5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.amjcard.2019.05.029","article-title":"Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy","volume":"124","author":"Fradley","year":"2019","journal-title":"Am J Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-Associated Atrial Fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2165\/11633140-000000000-00000","article-title":"Drug-induced atrial fibrillation","volume":"72","author":"Kaakeh","year":"2012","journal-title":"Drugs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson BL Yu","year":"2017","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1078155214561281","article-title":"A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib","volume":"22","author":"Lee","year":"2016","journal-title":"J Oncol Pharm Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41586-020-2797-4","article-title":"Cells of the adult human heart","volume":"588","author":"Litvinukov\u00e1","year":"2020","journal-title":"Nature."},{"key":"B12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ccep.2016.04.003","article-title":"Nonsustained ventricular tachycardia in the normal heart: risk stratification and management","volume":"8","author":"Marine","year":"2016","journal-title":"Card Electrophysiol Clin."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma."},{"key":"B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12872-016-0210-x","article-title":"Incidence and timing of potentially high-risk arrhythmias detected through long term continuous ambulatory electrocardiographic monitoring","volume":"16","author":"Solomon","year":"2016","journal-title":"BMC Cardiovasc Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.jacc.2004.08.053","article-title":"Drug-induced atrial fibrillation","volume":"44","author":"van der Hooft","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1080\/03007995.2019.1610370","article-title":"Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature review","volume":"35","author":"Yenikomshian","year":"2019","journal-title":"Curr Med Res Opin."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.792310\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T06:25:54Z","timestamp":1641191154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.792310\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":20,"alternative-id":["10.3389\/fcvm.2021.792310"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.792310","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"article-number":"792310"}}